Articles related to CME

Poor adherence to treatment is the biggest predictor in relapse in serious mental illnesses. In this 0.5-CME credit activity, the panel discusses key contributors to the adherence challenge and strategies for improving adherence – including use of newer, better tolerated therapies. Available in video, podcast, and text.

Following participation in this educational activity, hematologists/oncologists, nurses, pharmacists, and other members of the interprofessional team involved in the management of DLBCL patients should be better able to:

Because each patient reports unique challenges, there is no “one size fits all” approach to managing cancer-associated venous thrombosis (CAT). Thrombosis is a complication that HCPs are not recognizing early enough in the face of multiple options for appropriately treating and managing CAT; additionally, there is a lack of awareness of new CAT management clinical data. Although the morbidity and mortality of VTE in cancer patients remain high, unfortunately, its management is not given the same priority. And although recommendations suggest an individualized approach to managing these patients, clinical practice adoption is slow. Published guidelines and clinical trial data do not always correspond to real-world practice and prescribing practices. As a result, many existing CAT management protocols must be updated as new guidance is warranted.

This activity aims to educate the multidisciplinary care team treating pediatric ADHD, including psychiatrists, pediatricians, PCPs, pharmacists, and dietitians/nutritionists. After completion, participants will be better able to describe the role of dietary deficiencies of essential fatty acids (EFAs) and genetic variants of metabolism in the pathophysiology of ADHD; review the most recent data on the safety and efficacy of supplementation with EFAs for ADHD management in children and adolescents; differentiate dietary supplements from medical foods; and create personalized nutritional therapy plans for ADHD patients by considering the individual needs of each patient and the differences among available dietary products.

This educational activity aims to meet the needs of the interprofessional team responsible for managing patients with PNH. Upon completion of this activity, participants will be able to demonstrate a comprehensive understanding of the pathophysiology of PNH and its implications, identify the prevalence of the disease and the unmet needs of patients, articulate the clinical indicators of successful PNH management and their significance, interpret guidelines and distinguish between the safety profiles of current and upcoming PNH therapeutics, and gain knowledge about emerging data on drug classes and mechanisms, including EVH, IVH, anemia, and adherence to pharmacological treatments for PNH.

Medical oncologists, pathologists, gastroenterologists, and other oncology HCPs who participate in this CME activity should be better able to determine appropriate testing to personalize treatment for HER2+ metastatic colorectal cancer patients (mCRC) and summarize clinical data from existing and emerging treatment options for HER2+ mCRC patients.